Behçet's disease: recent advances in early diagnosis and effective treatment
- PMID: 18817637
- DOI: 10.1007/s11926-008-0057-y
Behçet's disease: recent advances in early diagnosis and effective treatment
Abstract
Behçet's disease (BD) is a chronic, multisystem, inflammatory disorder that is classified among the systemic vasculitidies. Its cause has yet to be determined, but genetic and environmental factors and immune dysregulation are thought to play a role in its pathogenesis. The diagnosis of the disease and recognition and separation from disorders that may mimic BD may be difficult, especially in areas where the disease is uncommon. Certainty as to the best treatments for the various manifestations of BD is often unclear due to limited randomized controlled trials. However, existing consensus statements and expert opinions should help to guide therapy. This review examines important recent contributions to help the clinician more readily recognize patients with the disease and institute appropriate care.
Similar articles
-
[Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].Vojnosanit Pregl. 2012 Feb;69(2):168-74. doi: 10.2298/vsp1202168z. Vojnosanit Pregl. 2012. PMID: 22500372 Serbian.
-
Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. doi: 10.1007/s10384-006-0425-y. Epub 2007 Jun 7. Jpn J Ophthalmol. 2007. PMID: 17554481
-
Management of vascular Behçet's disease.Int J Rheum Dis. 2019 Jan;22 Suppl 1:105-108. doi: 10.1111/1756-185X.13298. Epub 2018 Apr 17. Int J Rheum Dis. 2019. PMID: 29665281 Review.
-
[Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].Zhonghua Nei Ke Za Zhi. 2020 Apr 1;59(4):303-308. doi: 10.3760/cma.j.cn112138-20190730-00527. Zhonghua Nei Ke Za Zhi. 2020. PMID: 32209197 Chinese.
-
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17. Ophthalmology. 2014. PMID: 24359625
Cited by
-
MiR-146a and miR-155 polymorphisms in Egyptian patients with Behcet's disease.Arch Med Sci. 2021 Mar 19;18(6):1467-1474. doi: 10.5114/aoms/105349. eCollection 2022. Arch Med Sci. 2021. PMID: 36457982 Free PMC article.
-
Geographical variations in ocular and extra-ocular manifestations in Behçet's disease.Eur J Rheumatol. 2019 Jul 19;6(4):199-206. doi: 10.5152/eurjrheum.2019.18215. Print 2019 Oct. Eur J Rheumatol. 2019. PMID: 31329543 Free PMC article.
-
Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.Nat Rev Neurol. 2011 Nov 1;7(12):688-98. doi: 10.1038/nrneurol.2011.176. Nat Rev Neurol. 2011. PMID: 22045269 Review.
-
Diagnostic value of pathergy test in Behcet's disease according to the change of incidence over the time.Clin Rheumatol. 2011 Sep;30(9):1151-5. doi: 10.1007/s10067-011-1694-5. Epub 2011 Mar 2. Clin Rheumatol. 2011. PMID: 21365194
-
Evaluation of current therapeutic strategies in Behçet's disease.Clin Rheumatol. 2011 Feb;30(2):157-63. doi: 10.1007/s10067-010-1566-4. Epub 2010 Sep 15. Clin Rheumatol. 2011. PMID: 20842513 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical